Welcome to our dedicated page for Equillium SEC filings (Ticker: EQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Equillium, Inc. (Nasdaq: EQ) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Equillium is a clinical-stage biotechnology company based in La Jolla, California, focused on developing immunomodulatory therapies for severe autoimmune and inflammatory disorders, with its lead candidate EQ504 targeting the aryl hydrocarbon receptor (AhR).
Through this page, users can review Form 10-Q and 10-K reports, which include details on Equillium’s operating losses, cash resources, going concern language from auditors, and management’s discussion of risks and plans related to its immuno-inflammatory pipeline and financing needs. Form 8-K filings document material events such as private placement agreements to fund EQ504 development, amendments to at-the-market sale agreements, changes in independent registered public accounting firms, leadership and board updates, and the termination of collaboration and license agreements related to itolizumab with Biocon Limited.
Equillium’s filings also cover Nasdaq listing matters, including notices of non-compliance with minimum bid price requirements and subsequent confirmation of regained compliance. Additional disclosures describe the company’s adoption of a cryptocurrency treasury reserve strategy, amendments to its investment policy, and supplemental risk factors associated with digital asset holdings.
On Stock Titan, these documents are updated in near real time as they appear on EDGAR. AI-powered summaries help explain complex sections, highlight key points on topics such as EQ504 development plans, capital structure changes, and treasury strategy, and make it easier to identify items like equity issuances, open market sale agreements and auditor changes. Users can also quickly locate Form 4 and other ownership-related filings to track insider and major holder activity as it is reported.
Janus Henderson Group plc has filed an amended Schedule 13G reporting beneficial ownership of 6,083,239 shares of Equillium, Inc. common stock, representing 9.99% of the class. These holdings are managed through various affiliated asset managers on behalf of client accounts, called Managed Portfolios.
The position includes shares that may be obtained through exercise of certain pre-funded warrants that are exercisable within 60 days, but only to the extent total beneficial ownership does not exceed 9.99% of Equillium’s outstanding common stock. An additional 18,584,856 warrants are excluded from the reported figures due to this ownership cap. Dividends and sale proceeds belong to the Managed Portfolios, not Janus Henderson.
Equillium, Inc. granted its President and Chief Scientific Officer, Stephen Connelly, an employee stock option to buy 1,150,000 shares of common stock at an exercise price of
According to the vesting terms, 25% of the shares under the option vest on the first anniversary of the vesting commencement date, with the remaining shares vesting in 36 equal monthly installments over the following three years. After this grant, Connelly beneficially holds 1,150,000 stock options directly.
Equillium, Inc. reported that Sr. Vice President and COO Christine Zedelmayer received an employee stock option grant on 01/07/2026. The derivative award covers 500,000 stock options with an exercise price of $1.31 per share, allowing her to buy common stock at that price in the future. The grant was reported at a cost of $0 for the option itself and leaves her with 500,000 derivative securities beneficially owned directly after the transaction.
According to the vesting terms, 25% of the option vests on the first anniversary of the vesting commencement date, and the remaining options vest in 36 equal monthly installments over the following three years, resulting in a standard four-year vesting schedule tied to ongoing service.
Equillium, Inc. reported that its Chief Executive Officer, director and 10% owner, Bruce D. Steel, was granted an employee stock option on 01/07/2026. The option covers 1,750,000 shares of common stock at an exercise price of $1.31 per share and expires on 01/06/2036. According to the vesting terms, 25% of the shares vest on the first anniversary of the vesting commencement date, with the remaining shares vesting in 36 equal monthly installments over the following three years. After this grant, Steel beneficially holds 1,750,000 derivative securities directly.
Equillium, Inc. Principal Accounting Officer Tom Penny reported one stock sale and a new stock option grant. Penny sold 6,533 shares of common stock on January 8, 2026 at $1.29 per share, leaving him with no shares of common stock held directly after the sale. The filing notes these sales were made under a Rule 10b5-1 trading plan adopted on October 10, 2025, meaning they were pre‑scheduled rather than discretionary.
On January 7, 2026, Penny was granted an employee stock option to purchase 450,000 shares of Equillium common stock at an exercise price of $1.31 per share. The option vests over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining shares vesting in 36 equal monthly installments over the following three years. After this grant, he holds 450,000 stock options directly.
An employee shareholder of EQ has filed a notice of proposed sale on Form 144 to sell 6,533 shares of common stock. The shares are to be sold through Maxim Group, with an aggregate market value of $8,427.00, on the NASDAQ, with an approximate sale date of 01/08/2026. These shares were acquired on 06/18/2024 under an Employee Stock Purchase Plan from the issuer and were paid for in cash on 12/12/2025. The company had 60,893,283 shares of common stock outstanding at the time referenced in the notice.
Equillium’s Senior Vice President and Chief Operating Officer reported open-market sales of company common stock. On December 12, 2025, the executive sold 23,804 shares of Equillium common stock at a price of $1.34 per share. On December 15, 2025, an additional 11,900 shares were sold at $1.31 per share.
Following these transactions, the reporting person beneficially owned 91,444 shares of Equillium common stock in direct ownership. The filing notes that the reported sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2025, which is a pre-arranged plan for trading company stock.
Equillium, Inc. (EQ)11/25/2025, the officer sold 100 shares of common stock at $0.98 per share and another 7,998 shares at $0.95 per share. After these transactions, the officer beneficially owned 127,148 shares of Equillium common stock directly. The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2025, which is designed to allow insiders to sell shares according to a predetermined schedule.
Equillium, Inc. filed a shelf registration on Form S-3 to offer up to $250,000,000 of securities (common stock, preferred stock, debt, and warrants) from time to time, with terms to be set by prospectus supplements. The filing also includes a dedicated sales agreement prospectus for an at-the-market offering of up to $75,000,000 of common stock through LifeSci Capital, included within the $250,000,000 shelf.
Under the ATM, LifeSci Capital will act as sales agent on a commercially reasonable efforts basis, and will receive up to 3.0% of gross proceeds as compensation. Proceeds to the company will be used for general corporate purposes, including research and development, working capital, and capital expenditures, as later specified in supplements.
Equillium’s common stock trades on Nasdaq as “EQ,” and the last reported sale price was $0.924 per share on November 12, 2025. Shares outstanding were 60,676,837 as of September 30, 2025; this is a baseline figure, not the amount being offered.
Equillium, Inc. (EQ)$4.23 million$0 revenue$4.58 million
Cash and cash equivalents were $33.12 million$30.94 million~$30 million gross~$20 million~$0.9 million gross60,676,83760,893,283
The company terminated prior Biocon agreements and is focusing on EQ504through 2027.
FAQ
What is the current stock price of Equillium (EQ)?
What is the market cap of Equillium (EQ)?
